INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase…
Categorie
2022
MaaT Pharma Publishes its 2021 Annual Results and Provides a Business Overview As of December 31, 2021, cash and cash…
April 14, 2022
MaaT Pharma Announces the Initiation of a Phase 2a Investigator-Sponsored Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors…
April 7, 2022
Monthly information regarding the total number of voting rights and shares comprising the share capital Article 223-16 of the General…
April 4, 2022
MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease Pivotal Phase…
March 28, 2022
MaaT Pharma Announces the Implementation of a Liquidity Contract with Kepler Cheuvreux Lyon, France, March 21st, 2022 – 6:00 pm…
March 21, 2022
MaaT Pharma to Present Promising Clinical Data for Lead Therapeutic Candidate MaaT013 at 48th EBMT Annual Meeting Data from 76…
March 17, 2022
MaaT Pharma Reports Cash and Revenues for Full-Year 2021 As of December 31, 2021, cash and cash equivalents of positions…
February 28, 2022
Ce communiqué ne peut être distribué directement ou indirectement aux Etats-Unis d’Amérique, au Canada, en Australie, au Japon ou en…
February 9, 2022
[image_with_animation image_url=”6640″ animation=”Fade In” hover_animation=”none” alignment=”center” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default”][divider line_type=”No Line”] MaaT Pharma and Skyepharma Have Entered a…
February 8, 2022
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.